Oshiro Chiya, Kamigaki Shunji, Nakamura Yukio, Arai Takashi, Kanai Yukie, Fujino Misako, Fujii Chika, Hamaguchi Yoshiko, Iseki Chihiro, Hachino Yoshimi, Furukawa Hiroshi
Dept. of Surgery, Sakai Municipal Hospital, Japan.
Gan To Kagaku Ryoho. 2012 Feb;39(2):241-4.
Chemotherapy-induced nausea and vomiting(CINV)is one of the side effects causing significant psychological and physical suffering in patients receiving chemotherapy. Because CINV often impairs patients' quality of life and leads to discontinuation of treatments, antiemetic therapy has been considered important. The MASCC Antiemesis Tool(MAT)was proposed for the assessment of acute and delayed nausea and vomiting after, we evaluated the actual situation of nausea and vomiting for Japanese patients. In a previous investigation, even conventional antiemesis therapy was a highly effective treatment during the acute phase, but the control of nausea and vomiting during the delayed phase proved difficult. Recently, a new5 -HT3 receptor blocker(palonosetron)and an NK1 receptor blocker(aprepitant) were introduced, and an effective treatment of nausea and vomiting for the delayed phase is non expected. In this examination, we evaluated the usefulness of the new antiemetic drugs(palonosetron and aprepitant)in 12 prospective patients with breast cancer(40-69 years old, median age 53 years old)for whom FEC therapy was given as an ambulant treatment using MAT. No vomiting occurred in the acute and delayed phase. Nausea during the acute phase was controlled, and was mild during the delayed phase, also. It was confirmed that the onset of acute and delayed nausea and vomiting were relieved by the newantiemetic agents compared with the previous MAT evaluation.
化疗引起的恶心和呕吐（CINV）是接受化疗的患者出现的副作用之一，会给患者带来严重的身心痛苦。由于CINV常常损害患者的生活质量并导致治疗中断，因此止吐治疗一直被认为很重要。MASCC止吐工具（MAT）被用于评估化疗后急性和迟发性恶心和呕吐，我们评估了日本患者恶心和呕吐的实际情况。在之前的一项调查中，即使是传统的止吐治疗在急性期也是一种高效的治疗方法，但事实证明，控制迟发性恶心和呕吐很困难。最近，一种新型5-羟色胺3（5-HT3）受体阻滞剂（帕洛诺司琼）和一种神经激肽1（NK1）受体阻滞剂（阿瑞匹坦）被引入，预计对迟发性恶心和呕吐有有效的治疗作用。在本次检查中，我们使用MAT评估了12例接受氟尿嘧啶-表柔比星-环磷酰胺（FEC）门诊化疗的前瞻性乳腺癌患者（年龄40 - 69岁，中位年龄53岁）使用新型止吐药物（帕洛诺司琼和阿瑞匹坦）的有效性。急性和迟发性阶段均未发生呕吐。急性期的恶心得到了控制，迟发性阶段的恶心也很轻微。与之前的MAT评估相比，证实新型止吐药缓解了急性和迟发性恶心和呕吐的发作。
